418 related articles for article (PubMed ID: 22939047)
1. Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria.
Iskrov G; Miteva-Katrandzhieva T; Stefanov R
Health Policy; 2012 Nov; 108(1):10-8. PubMed ID: 22939047
[TBL] [Abstract][Full Text] [Related]
2. Access to orphan drugs in Europe: current and future issues.
Michel M; Toumi M
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
[TBL] [Abstract][Full Text] [Related]
3. Market uptake of orphan drugs--a European analysis.
Picavet E; Annemans L; Cleemput I; Cassiman D; Simoens S
J Clin Pharm Ther; 2012 Dec; 37(6):664-7. PubMed ID: 22731105
[TBL] [Abstract][Full Text] [Related]
4. Access to orphan drugs - comparison across Balkan countries.
Pejcic AV; Iskrov G; Jakovljevic MM; Stefanov R
Health Policy; 2018 Jun; 122(6):583-589. PubMed ID: 29729905
[TBL] [Abstract][Full Text] [Related]
5. [Orphan drugs in France (2001-2005): access to information and characteristics].
Baumevieille M; Daveluy A; Aulois-Griot M; Haramburu F
Therapie; 2007; 62(1):9-16. PubMed ID: 17374342
[TBL] [Abstract][Full Text] [Related]
6. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
7. Assessing the economic challenges posed by orphan drugs.
Drummond MF; Wilson DA; Kanavos P; Ubel P; Rovira J
Int J Technol Assess Health Care; 2007; 23(1):36-42. PubMed ID: 17234015
[TBL] [Abstract][Full Text] [Related]
8. [Orphan drugs: some legal, ethical and economics aspects].
Pabst JY
Rev Epidemiol Sante Publique; 2001 Sep; 49(4):387-96. PubMed ID: 11567205
[TBL] [Abstract][Full Text] [Related]
9. [Authorization and reimbursement of orphan drugs in an international comparison].
Roll K; Stargardt T; Schreyögg J
Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
[TBL] [Abstract][Full Text] [Related]
10. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
Hughes-Wilson W; Palma A; Schuurman A; Simoens S
Orphanet J Rare Dis; 2012 Sep; 7():74. PubMed ID: 23013790
[TBL] [Abstract][Full Text] [Related]
11. Issues surrounding orphan disease and orphan drug policies in Europe.
Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
Appl Health Econ Health Policy; 2010; 8(5):343-50. PubMed ID: 20804226
[TBL] [Abstract][Full Text] [Related]
12. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
13. The European challenges of funding orphan medicinal products.
Szegedi M; Zelei T; Arickx F; Bucsics A; Cohn-Zanchetta E; Fürst J; Kamusheva M; Kawalec P; Petrova G; Slaby J; Stawowczyk E; Vocelka M; Zechmeister-Koss I; Kaló Z; Molnár MJ
Orphanet J Rare Dis; 2018 Nov; 13(1):184. PubMed ID: 30396361
[TBL] [Abstract][Full Text] [Related]
14. Analysing criteria for price and reimbursement of orphan drugs in Spain.
Badia X; Gil A; Poveda-Andrés JL; Shepherd J; Tort M
Farm Hosp; 2019 Jul; 43(4):121-127. PubMed ID: 31276443
[TBL] [Abstract][Full Text] [Related]
15. [European ordinance on orphan drugs: changes and threats].
Linthorst GE; Hollak CE
Ned Tijdschr Geneeskd; 2003 Jan; 147(4):143-5. PubMed ID: 12635543
[TBL] [Abstract][Full Text] [Related]
16. Policies and availability of orphan medicines in outpatient care in 24 European countries.
Sarnola K; Ahonen R; Martikainen JE; Timonen J
Eur J Clin Pharmacol; 2018 Jul; 74(7):895-902. PubMed ID: 29632962
[TBL] [Abstract][Full Text] [Related]
17. Insight into reimbursement decision-making criteria in Bulgaria: implications for orphan drugs.
Iskrov GG; Raycheva RD; Stefanov RS
Folia Med (Plovdiv); 2013; 55(3-4):80-6. PubMed ID: 24712287
[TBL] [Abstract][Full Text] [Related]
18. [Orphan drugs: availability, reliability and reimbursement].
Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ
Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041
[TBL] [Abstract][Full Text] [Related]
19. Dutch doctors call for EU evaluation of cost effectiveness of high cost orphan drugs.
Sheldon T
BMJ; 2012 Aug; 345():e5461. PubMed ID: 22890124
[No Abstract] [Full Text] [Related]
20. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
Zelei T; Molnár MJ; Szegedi M; Kaló Z
Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]